Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Palisade Bio ( (PALI) ) just unveiled an announcement.
On September 18, 2025, Palisade Bio, Inc. adjourned a special meeting of stockholders due to insufficient shares present to constitute a quorum. The meeting is rescheduled for September 26, 2025, with no changes to the proposals to be voted on, allowing stockholders to maintain their previous votes if desired.
The most recent analyst rating on (PALI) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
Palisade Bio’s financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.
To see Spark’s full report on PALI stock, click here.
More about Palisade Bio
Palisade Bio, Inc. operates in the biotechnology industry, focusing on developing therapies for acute and chronic gastrointestinal complications.
Average Trading Volume: 2,397,621
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.27M
For detailed information about PALI stock, go to TipRanks’ Stock Analysis page.